title: Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone.
authors.forename: Y H
authors.initials: YH
authors.lastname: Park
authors.forename: S
authors.initials: S
authors.lastname: Kim
authors.forename: S-J
authors.initials: SJ
authors.lastname: Choi
authors.forename: B-Y
authors.initials: BY
authors.lastname: Ryoo
authors.forename: S H
authors.initials: SH
authors.lastname: Yang
authors.forename: G J
authors.initials: GJ
authors.lastname: Cheon
authors.forename: C-W
authors.initials: CW
authors.lastname: Choi
authors.forename: S M
authors.initials: SM
authors.lastname: Lim
authors.forename: J Y
authors.initials: JY
authors.lastname: Yoo
authors.forename: S-S
authors.initials: SS
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy*; D003657:Decision Making; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008223:Lymphoma / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed; D016896:Treatment Outcome; D014915:Whole-Body Counting
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18